71 related articles for article (PubMed ID: 26394887)
1. Circulating hepcidin in type 2 diabetes: A multivariate analysis and double blind evaluation of metformin effects.
Suárez-Ortegón MF; Moreno M; Arbeláez A; Xifra G; Mosquera M; Moreno-Navarrete JM; Aguilar-de Plata C; Esteve E; Ricart W; Fernández-Real JM
Mol Nutr Food Res; 2015 Dec; 59(12):2460-70. PubMed ID: 26394887
[TBL] [Abstract][Full Text] [Related]
2. Association between ferritin and hepcidin levels and inflammatory status in patients with type 2 diabetes mellitus and obesity.
Andrews M; Soto N; Arredondo-Olguín M
Nutrition; 2015 Jan; 31(1):51-7. PubMed ID: 25441587
[TBL] [Abstract][Full Text] [Related]
3. Association of Hepcidin levels in Type 2 Diabetes Mellitus treated with metformin or combined anti-diabetic agents in Pakistani population.
Najeeb T; Soomro Late MS; Fawwad A; Waris N; Nangrejo R; Siddiqui IA; Aziz Q; Basit A
J Pak Med Assoc; 2023 Feb; 73(2):313-318. PubMed ID: 36800717
[TBL] [Abstract][Full Text] [Related]
4. Hepcidin levels in diabetes mellitus and polycystic ovary syndrome.
Sam AH; Busbridge M; Amin A; Webber L; White D; Franks S; Martin NM; Sleeth M; Ismail NA; Daud NM; Papamargaritis D; Le Roux CW; Chapman RS; Frost G; Bloom SR; Murphy KG
Diabet Med; 2013 Dec; 30(12):1495-9. PubMed ID: 23796160
[TBL] [Abstract][Full Text] [Related]
5. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
6. Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome.
Luque-Ramírez M; Álvarez-Blasco F; Alpañés M; Escobar-Morreale HF
J Clin Endocrinol Metab; 2011 Mar; 96(3):846-52. PubMed ID: 21209031
[TBL] [Abstract][Full Text] [Related]
7. Effect of testosterone on hepcidin, ferroportin, ferritin and iron binding capacity in patients with hypogonadotropic hypogonadism and type 2 diabetes.
Dhindsa S; Ghanim H; Batra M; Kuhadiya ND; Abuaysheh S; Green K; Makdissi A; Chaudhuri A; Dandona P
Clin Endocrinol (Oxf); 2016 Nov; 85(5):772-780. PubMed ID: 27292585
[TBL] [Abstract][Full Text] [Related]
8. Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus.
Sharma PK; Bhansali A; Sialy R; Malhotra S; Pandhi P
Clin Endocrinol (Oxf); 2006 Dec; 65(6):722-8. PubMed ID: 17121522
[TBL] [Abstract][Full Text] [Related]
9. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
10. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
11. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
12. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial.
De Jager J; Kooy A; Lehert P; Bets D; Wulffelé MG; Teerlink T; Scheffer PG; Schalkwijk CG; Donker AJ; Stehouwer CD
J Intern Med; 2005 Jan; 257(1):100-9. PubMed ID: 15606381
[TBL] [Abstract][Full Text] [Related]
13. Association between metformin use and below-the-knee arterial calcification score in type 2 diabetic patients.
Mary A; Hartemann A; Liabeuf S; Aubert CE; Kemel S; Salem JE; Cluzel P; Lenglet A; Massy ZA; Lalau JD; Mentaverri R; Bourron O; Kamel S
Cardiovasc Diabetol; 2017 Feb; 16(1):24. PubMed ID: 28202017
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.
Esteghamati A; Afarideh M; Feyzi S; Noshad S; Nakhjavani M
Diabetes Metab Syndr; 2015; 9(4):258-65. PubMed ID: 25450818
[TBL] [Abstract][Full Text] [Related]
15. Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial.
Esposito K; Maiorino MI; Di Palo C; Gicchino M; Petrizzo M; Bellastella G; Saccomanno F; Giugliano D
Diabetes Obes Metab; 2011 May; 13(5):439-45. PubMed ID: 21255215
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
DeFronzo RA; Burant CF; Fleck P; Wilson C; Mekki Q; Pratley RE
J Clin Endocrinol Metab; 2012 May; 97(5):1615-22. PubMed ID: 22419732
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
[TBL] [Abstract][Full Text] [Related]
19. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]